CURRENT INNOVATIONS by

1. CRISPR TECHNOLOGY

vessman — 2024-02-27 04:34:25 UTC

2. SOURCE: SCIENCE.ORG AUTHORS: JOY Y. WANG & JENNIFER A. DOUDNA

vessman — 2024-02-27 04:41:28 UTC

"J.A.D. is a cofounder of Caribou Biosciences, Editas Medicine, Scribe Therapeutics, Intellia Therapeutics and Mammoth Biosciences. J.A.D. is a scientific advisory board member of Vertex, Caribou Biosciences, Intellia Therapeutics, Scribe Therapeutics, Mammoth Biosciences, Algen Biotechnologies, Felix Biosciences, The Column Group and Inari. J.A.D. is the chief science advisor of Sixth Street, is on the board of directors at Altos, Johnson & Johnson, and Tempus, and has research projects sponsored by AppleTree Partners and Roche. The Regents of the University of California have patents issued and pending for CRISPR technologies on which J.A.D. is named as an inventor (Wang & Doudna, 2023)."

"J.Y.W. was supported by a US National Science Foundation Graduate Fellowship. J.A.D. is a Howard Hughes Medical Institute investigator (Wang & Doudna, 2023)."

3. DATE PUBLISHED: 20 JAN 2023

vessman — 2024-02-27 04:42:19 UTC

4. SUMMARY OF CURRENT INNOVATION

vessman — 2024-02-27 04:47:07 UTC

"The advent of clustered regularly interspaced short palindromic repeat (CRISPR) genome editing, coupled with advances in computing and imaging capabilities, has initiated a new era in which genetic diseases and individual disease susceptibilities are both predictable and actionable. Likewise, genes responsible for plant traits can be identified and altered quickly, transforming the pace of agricultural research and plant breeding (Wang & Doudna, 2023)."

5.

vessman — 2024-02-27 04:47:30 UTC

6. PROS

vessman — 2024-02-27 04:58:48 UTC

CRISPR-Cas9 CAN FIND PATHOGENIC GENES, COMPENSATE FOR THE PATHOGENIC GENE, AND REVERSE A DISEASE

7. CONS

vessman — 2024-02-27 05:02:50 UTC

-OFF-TARGET GENOME EDITING EFFECTS

-CAN INDUCE SITE-SPECIFIC DNA MUTATIONS IN HUMAN DNA

8. OPINION AND RATIONALE

vessman — 2024-02-27 05:12:42 UTC

MY OPINION IS THAT CRISPR TECHNOLOGY HAS ENORMOUS POTENTIAL TO REVERSE GENETIC MUTATIONS. FUNDING IS NEEDED AND REQUIRED TO SUPPORT PATIENTS WHO SUFFER FROM DEBILITATING CONDITIONS. I SEE THE NEED DIRECTLY IN MY PATIENT POPULATION OF PEDIATRICS. I BELIEVE THAT ONE OF MY PATIENTS IN PARTICULAR, WHO HAS A GENETIC MUTATION "SLC13A5", COULD GREATLY BENEFIT FROM GENE THERAPY. UNFORTUNATELY, RARE CONDITIONS LIKE THIS ARE UNLIKELY TO BE DISCOVERED WITHOUT THOROUGH GENE TESTING, AND WITHOUT RECOGNITION OF HOW WIDESPREAD THE DISEASE IS, THE FUNDING DOES NOT BACK THE CLINICAL RESEARCH/TRIALS. THIS GENE MUTATION LIMITS ALL OF HIS FUNCTION ABILITIES, INCLUDING WALKING, TALKING, SWALLOWING, ETC. CRISPR TECHNOLOGY CAN POTENTIALLY COMPENSATE FOR THE PATHOGENIC GENE AND REVERSE THE DISEASE.

9. TEAMS

vessman — 2024-02-27 05:23:44 UTC

TOP FIVE STRENGTHS:

ADAPTABILITY

POSITIVITY

INPUT

FUTURISTIC

INCLUDER

-----------

I BELIEVE MY STRENGTHS WILL HELP THE TEAM BY BEING ABLE TO ADAPT TO DIFFERENT CIRCUMSTANCES OR SITUATIONS, KEEPING THE TEAM MORALE UP WITH POSITIVITY, GIVING GOOD INPUT TO CONTRIBUTE TO THE PROJECT, THINKING FUTURISTICALLY, AND ALWAYS BEING INCLUSIVE, GIVING EVERY INDIVIDUAL A SENSE OF UNITY.

FERNANDO (FOCUS)- I CHOSE FERNANDO BECAUSE I NEED A TEAM MEMBER WHO IS FOCUSED, STAYS ON TASK, AND CAN STAY CONSISTENT WITH ORGANIZING AND PLANNING.

CARTER (COMMUNICATION)- I CHOSE CARTER BECAUSE EVERY TEAM REQUIRES EFFECTIVE COMMUNICATION TO BE SUCCESSFUL, I THINK CARTER WOULD BE A GREAT ATTRIBUTE TO THE TEAM.

DANIEL (DISCIPLINE)- I CHOSE DANIEL BECAUSE I AM NATURALLY A DAY-DREAMER, SPONTANEOUS, AND UNORGANIZED. I THINK A STRENGTH LIKE DISCIPLINE WOULD HELP REEL ME BACK IN AND HELP THE TEAM STAY STRUCTURED WITH ROUTINE.

ALICE (ACHIEVER)- I CHOSE ALICE BECAUSE I BELIEVE THAT AN ACHIEVER WILL BE MORE LIKELY TO ACCOMPLISH SET GOALS, A GREAT ADDITION TO THE TEAM.

CARLEE (CONSISTENCY)- I CHOSE CARLEE BECAUSE CONSISTENCY IS THE MOST PRODUCTIVE WAY TO COMPLETE A PROJECT OR ASSIGNMENT.

10. REFERENCES

vessman — 2024-02-27 05:36:00 UTC

Wang, J. Y., & Doudna, J. A. (2023). CRISPR technology: A Decade of genome editing is only the beginning. Science, 379(6629). https://doi.org/10.1126/science.add8643